AUG 14·SEC EDGARLow
Espinoza Octavio sold $9.2M of LGND
Espinoza Octavio (Chief Financial Officer) sold 31,641 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.06 ($9.24M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$LGND
LIGAND PHARMACEUTICALS INC
Price · $LGNDvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $12.8M 12 txs
Reardon Andrew10× · $1.4M
10b5-1 share of filings92%
Top stories · $LGNDMore →
AUG 14·SEC EDGAR
Haas Jason sold $2.1M of LGND
Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
AUG 13·fool.com
Ligand (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.
LGND sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning LGND (LIGAND PHARMACEUTICALS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LGND coverage spans insider activity, earnings and mergers & acquisitions.
In the last 30 days, LGND insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($12.8M). The most active reporter was Reardon Andrew, CLO & Secretary, with 10 filings. 92% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving LGND
The filing is a direct insider sale by the CFO under a 10b5-1 plan, which can modestly affect sentiment but is not a fundamental change by itself.
An insider open-market sale is disclosed, but the filing provides no new operational or guidance catalyst.
Guidance raise plus capital deployment (convertible notes) and XOMA Royalty scale/diversification are likely to support near-term sentiment, but execution and partner royalty variability remain key risks.
The earnings call summary provides fresh, quantified guidance and acquisition integration expectations that can drive near-term repricing and positioning.
Raised low-end adjusted EPS guidance alongside strong royalty growth and a $700M 0% convertible financing, plus acquisition of XOMA Royalty.
alphai scores every news story that mentions LGND with an AI model for sentiment and relevance, and aggregates insider trades from LIGAND PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $LGND
Score
Espinoza Octavio sold $9.2M of LGND
Espinoza Octavio (Chief Financial Officer) sold 31,641 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.06 ($9.24M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
1 min readHaas Jason sold $2.1M of LGND
Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
1 min read
Ligand (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.
6 min readLigand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary
Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.
7 min readLIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Confer
6 min readReardon Andrew sold $1.4M of LGND
Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $288.99 ($284.14–$292.82, $1.44M total) across 10 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min read
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
Wall Street futures rose Tuesday after major U.S. indices fell Monday. The article lists analyst rating changes and price targets for stocks including Adobe (ADBE) downgraded to Underweight with a $240 target, Salesforce (CRM) cut to Equal Weight with a $185 target, and Microsoft (MSFT) assumed Overweight with a $600 target. It also cites moves for Datadog, Fortinet, Five Below, Gilead, and others.
4 min read
XOMA Royalty Announces Closing of Its Acquisition by Ligand
XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.
2 min read
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).
3 min readLIGAND PHARMACEUTICALS INC (LGND): Completion of Acquisition or Disposition of Assets
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest
4 min read